JOINT VENTURE AGREEMENTJoint Venture Agreement • April 28th, 2021 • Silo Pharma, Inc. • Apparel & other finishd prods of fabrics & similar matl • Delaware
This Joint Venture Agreement (the “Agreement”) is made and entered into this 22nd day of April, 2021 (the “Effective Date”), by and between Silo Pharma, Inc., a Delaware Corporation (“Silo”) and Zylö Therapeutics, Inc., a Delaware corporation (“ZTI”), for the formation of [Ketamine Joint Venture, LLC] (the “Joint Venture”). Silo and ZTI are severally referred to herein as a “Joint Venturer” and collectively as the “Joint Venturers.” The names, addresses, and interests of the Joint Venturers in the Joint Venture are listed in Exhibit A attached hereto and incorporated herein by reference for all purposes.
ContractSilo Pharma, Inc. • April 28th, 2021 • Apparel & other finishd prods of fabrics & similar matl
Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics
